Lead Product(s) : Propagermanium
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial
Details : Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients, 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo.
Brand Name : DMX-200
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2020
Lead Product(s) : Propagermanium
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?